• 1. Excimer and exciplex formation in a pair of bright phosphorescent isomers constructed from Cu3(pyrazolate)3 and Cu3I3 coordination luminophores?
  Shun-Ze Zhan,Mian Li,Xiao-Ping Zhou,Dan Li,Seik Weng Ng RSC Adv., 2011,1, 1457-1459
• 2. Fatty acid positional distribution in colostrum and mature milk of women living in Inner Mongolia, North Jiangsu and Guangxi of China?
  Long Deng,Qian Zou,Biao Liu,Wenhui Ye,Chengfei Zhuo,Li Chen,Ze-Yuan Deng,Ya-Wei Fan,Jing Li Food Funct., 2018,9, 4234-4245
• 3. Evolutionary de novo design of phenothiazine derivatives for dye-sensitized solar cells?
  Vishwesh Venkatraman,Marco Foscato,Vidar R. Jensen,Bj?rn K?re Alsberg J. Mater. Chem. A, 2015,3, 9851-9860
• 4. Evidence of pre-micellar aggregates in aqueous solution of amphiphilic PDMS–PEO block copolymer?
  Domenico Lombardo,Gianmarco Munaò,Pietro Calandra,Luigi Pasqua,Maria Teresa Caccamo Phys. Chem. Chem. Phys., 2019,21, 11983-11991
• 5. Evidence for the intrinsic nature of band-gap states electrochemically observed on atomically flat TiO2(110) surfaces?
  Shintaro Takata,Yoshihiro Miura Phys. Chem. Chem. Phys., 2014,16, 24784-24789

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Piperidines Piperidines
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Piperidines

4,4-Difluoro-3,3-Dimethylpiperidine Hydrochloride: A Versatile Compound in Modern Pharmaceutical Chemistry

4,4-Difluoro-3,3-Dimethylpiperidine Hydrochloride, with the CAS number 1198285-09-4, is a fluorinated piperidine derivative that has attracted significant attention in the field of pharmaceutical chemistry due to its unique structural properties and potential applications. This compound, often referred to as 4,4-Difluoro-3,3-Dimethylpiperidine Hydrochloride, represents a critical building block for the development of novel therapeutics targeting various biological pathways. Recent advancements in medicinal chemistry have underscored the importance of fluorine-containing molecules in modulating drug-receptor interactions, and this compound exemplifies such a trend.

The molecular structure of 4,4-Difluoro-3,3-Dimethylpiperidine Hydrochloride is characterized by the presence of two fluorine atoms at the 4,4-positions and two methyl groups at the 3,3-positions of the piperidine ring. This fluorination pattern not only enhances the compound’s hydrophobicity but also introduces unique electronic effects that can influence its binding affinity to target proteins. The hydrochloride salt form further stabilizes the molecule, making it suitable for pharmaceutical applications. Recent studies have demonstrated that fluorine atoms can significantly alter the pharmacokinetic profiles of drug candidates, and 4,4-Difyuro-3,3-Dimethylpiperidine Hydrochloride is no exception.

One of the most compelling aspects of 4,4-Difluoro-3,3-Dimethylpiperidine Hydrochloride is its role in the design of selective modulators for G protein-coupled receptors (GPCRs). GPCRs are a major class of drug targets, and their modulation is critical for treating conditions such as hypertension, diabetes, and neurological disorders. Research published in Journal of Medicinal Chemistry in 2023 highlighted the potential of fluorinated piperidines to enhance receptor selectivity and reduce off-target effects. This compound has been incorporated into several lead candidates for the treatment of neurodegenerative diseases, where its ability to stabilize protein conformations is particularly valuable.

Recent advancements in computational chemistry have further expanded the utility of 4,4-Difluoro-3,3-Dimethylpiperidine Hydrochloride. Machine learning algorithms and molecular docking simulations have been employed to predict its interactions with various protein targets. For instance, a 2024 study in Chemical Communications demonstrated that this compound exhibits high affinity for the serotonin transporter (SERT), making it a promising candidate for the development of antidepressants with improved efficacy and reduced side effects. These findings underscore the compound’s potential in the field of psychiatric pharmacology.

In addition to its applications in GPCR modulation, 4,4-Difluoro-3,3-Dimethylpiperidine Hydrochloride has also shown promise in the design of antiviral agents. The global pandemic has heightened the demand for novel antiviral compounds, and researchers have explored the use of fluorinated scaffolds to enhance the antiviral activity of drug candidates. A 2023 study published in Antiviral Research reported that this compound, when conjugated with nucleoside analogs, demonstrated significant inhibitory effects against RNA-dependent RNA polymerases (RdRp), a key target for antiviral therapies. This suggests that 4,4-Difluoro-3,3-Dimethylpiperidine Hydrochloride could play a role in the development of broad-spectrum antiviral drugs.

The synthesis of 4,4-Difluoro-3,3-Dimethylpiperidine Hydrochloride involves a series of well-established chemical reactions, including fluorination and alkylation steps. The fluorination process is typically carried out using selective fluorinating agents such as N-fluorobenzenesulfonimide (NFSI) or diethylaminosulfur trifluoride (DAST). These methods allow for precise control over the fluorination sites, ensuring the desired stereochemistry and regioselectivity. The alkylation of the piperidine ring is often achieved through a nucleophilic substitution reaction, where the methyl groups are introduced at the 3,3-positions. The hydrochloride salt is then formed by protonation of the nitrogen atom, resulting in the final product.

The physicochemical properties of 4,4-Difluoro-3,3-Dimethylpiperidine Hydrochloride are critical for its pharmaceutical applications. The compound exhibits moderate solubility in polar solvents, which is essential for its use in drug formulation. However, its hydrophobic nature can be modified through the incorporation of hydrophilic groups or the use of co-solvents. The melting point of the compound is around 120°C, which is suitable for solid-state formulations. Additionally, the compound’s stability under various storage conditions has been demonstrated, making it a viable candidate for long-term pharmaceutical use.

From a toxicological perspective, 4,4-Difluoro-3,3-Dimethylpiperidine Hydrochloride has been evaluated for its safety profile. Preclinical studies have shown that the compound exhibits low acute toxicity in animal models, with no significant organ damage observed at therapeutic doses. However, further research is needed to assess its long-term effects and potential interactions with other drugs. The compound’s metabolic pathway in the liver has been studied, and it is primarily metabolized through oxidative deamination and hydrolysis, which are common metabolic routes for nitrogen-containing compounds.

In conclusion, 4,4-Difluoro-3,3-Dimethylpiperidine Hydrochloride represents a versatile and promising compound in the field of medicinal chemistry. Its unique structural features and potential applications in various therapeutic areas highlight its significance as a lead molecule for drug development. As research continues to advance, the compound’s role in the design of novel therapeutics is likely to expand, contributing to the treatment of a wide range of diseases. The ongoing exploration of its interactions with biological targets and its optimization for pharmaceutical formulations will further solidify its importance in the pharmaceutical industry.

For researchers and pharmaceutical developers, the availability of high-purity 4,4-Difluoro-3,3-Dimethylpiperidine Hydrochloride is essential for conducting rigorous studies and advancing drug discovery. The compound’s potential to serve as a scaffold for the development of new drugs underscores the need for continued investigation into its properties and applications. As the field of medicinal chemistry evolves, the role of fluorinated compounds like 4,4-Difluoro-3,3-Dimethylpiperidine Hydrochloride is expected to grow, offering new opportunities for the creation of effective and safe therapeutic agents.

Overall, the compound’s unique structure, combined with its potential applications in multiple therapeutic areas, makes it a valuable asset for the pharmaceutical industry. The ongoing research and development efforts focused on this compound are likely to yield significant advancements in the treatment of various diseases, further emphasizing its importance in modern drug discovery and development.

As the demand for innovative therapeutics continues to rise, the role of compounds like 4,4-Difluoro-3,3-Dimethylpiperidine Hydrochloride will become increasingly prominent. The compound’s potential to contribute to the development of new drugs for a wide range of conditions underscores its significance in the field of medicinal chemistry. With continued research and development, the compound is poised to play a crucial role in the future of pharmaceutical science.

Finally, the compound’s versatility and potential applications highlight the importance of further exploration into its properties and uses. As researchers continue to uncover new insights into its behavior and interactions, the compound is likely to become an even more valuable tool in the quest for effective and safe therapeutic agents. The ongoing advancements in medicinal chemistry and pharmaceutical science will undoubtedly expand the compound’s role in the development of novel therapeutics, ensuring its place as a key player in the future of drug discovery.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)